M&A - Traws Pharma, Inc.

Form Type: 10-Q

Filing Date: 2025-05-15

Corporate Action: Merger

Type: New

Accession Number: 000155837025007872

Filing Summary: Traws Pharma, Inc., previously known as Onconova Therapeutics, Inc., incorporated in Delaware, reports a quarterly update for the period ended March 31, 2025. The document indicates a recent merger with Trawsfynydd Therapeutics, Inc. on April 1, 2024, which has resulted in a name change and strategic realignment focusing on advanced therapeutic developments. The merger is accounted for as an asset acquisition, consolidating significant clinical programs targeting respiratory viral diseases. As of March 31, 2025, the company recorded total assets of $19,063,000, with a reported net income of $21,490,000 attributable to the significant change in the fair value of warrant liability. Operating expenses were noted, particularly in research and development, totaling $2,506,000. The report mentions compliance with Nasdaq's continued listing requirements following earlier notifications of non-compliance. The company will continue to seek additional funding, highlighting liquidity concerns as it anticipates ongoing operating losses.

Form Type: 10-K

Filing Date: 2025-03-31

Corporate Action: Merger

Type: Update

Accession Number: 000155837025004165

Filing Summary: Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing therapies for respiratory viral diseases. Following a merger with Trawsfynydd Therapeutics, Inc. on April 1, 2024, Traws expanded its portfolio to include drugs targeting influenza and COVID-19. The company is advancing programs including tivoxavir marboxil for bird flu and seasonal influenza treatment, ratutrelvir targeting the SARS-CoV-2 virus, narazaciclib for treating solid tumors, and rigosertib for various cancers. The report highlights the necessity for ongoing financing for clinical trials and operational needs, while emphasizing the risks and uncertainties affecting the company's operations and financial condition.